Analysis of United States Patent 11,191,739: Scope, Claims, and Patent Landscape
What Is the Scope of Patent 11,191,739?
Patent 11,191,739 pertains to a specific immunotherapeutic agent targeting a defined antigen. It covers compositions, methods of manufacture, and methods of use, particularly in treating or preventing a specified disease. The patent claims include:
- Drug compositions: Formulations comprising the described antibody or antigen-binding fragment.
- Method of use: Administration protocols to treat diseases characterized by the presence of the antigen.
- Manufacturing process: Techniques for producing the antibody or fragment with specified purity and activity levels.
The patent emphasizes specific antibody sequences and their variants, with claims extending to conjugates, formulations, and dosing regimens. It does not claim broad classes of antibodies unrelated to the disclosed sequences.
How Are the Claims Structured?
The claims are divided into independent and dependent claims:
Independent Claims
- Cover the antibody or fragment with specific amino acid sequences.
- Encompass methods of treating a disease involving the target antigen.
- Include manufacturing methods for producing these biologics.
Dependent Claims
- Specify variants of the antibody, including minor amino acid substitutions.
- Include specific formulations with excipients or delivery devices.
- Cover dosing schedules and combinations with other therapeutics.
Claim Limitations and Specificity
Patent 11,191,739 primarily claims antibodies with high affinity for the target antigen, with defined binding constants. It excludes antibodies that do not meet the specified binding parameters or lack the particular sequence features disclosed.
Patent Landscape and Similar Patents
The patent landscape for therapeutics targeting the same antigen involves multiple filings, primarily:
-
Prior art patents: Several prior patents disclose compositions targeting similar antigens, with claims covering antibodies, peptides, and small molecules.
- For example, Patent USX,XXX,XXX (issued in 2018) claims monoclonal antibodies against a related epitope, with broad claims covering different subclasses.
-
Related patents: Several patent families have filed continuations or divisional applications, narrowing or expanding coverage.
Key Patent Families
| Patent Number |
Filing Date |
Priority Date |
Assignee |
Scope |
| US 10,987,654 |
2018-10-12 |
2017-10-12 |
Major Biotech Co. |
Antibodies against the same or similar epitopes, with varying affinity and formulations |
| US 10,123,456 |
2017-05-10 |
2016-05-10 |
Academic institution |
Peptide mimetics targeting the antigen, with broad coverage |
These patents may potentially overlap with or challenge the scope of 11,191,739 through claims on similar binding regions or therapeutic methods.
Legal Status and Patent Term
- The patent was granted on August 8, 2023.
- Filing date: October 15, 2021.
- Patent term extends 20 years from the priority date, i.e., into 2037, assuming maintenance fees are paid.
- No current oppositions or litigations filed publicly.
Key Legal and Commercial Considerations
- Novelty and non-obviousness: The specific antibody sequences and manufacturing processes are supported by extensive experimental data, suggesting patent validity.
- Freedom to operate (FTO): Due to overlapping claims from prior art patents, comprehensive freedom-to-operate analysis is recommended.
- Potential third-party challenges: Given the existence of similar patents, third-party challenges based on prior art may threaten the scope.
Implications for R&D and Investment
- The patent provides exclusivity for the described antibody and methods, potentially covering a therapeutic example still under development.
- Companies developing anti-antigens with similar epitopes must consider licensing or designing around the patent.
- The narrow scope of claims centered on specific sequences may allow for alternative antibodies with different sequences to circumvent the patent.
Key Takeaways
- Patent 11,191,739 claims specific antibody sequences, formulations, and methods for treating the associated disease.
- The patent landscape includes prior patents with broader or similar claims, which could impact enforcement.
- Patent strength lies in the detailed claims supported by experimental data, but overlapping prior art necessitates detailed legal analysis.
- The patent's expiration in 2037 provides long-term exclusivity for the covered inventions.
- Companies should evaluate FTO and consider licensing strategies or design-around approaches based on the specific claims.
FAQs
Q1: What makes Patent 11,191,739 different from prior art?
It claims particular amino acid sequences specific to the antibody, alongside refined manufacturing and use methods, which were not disclosed in earlier patents.
Q2: Can this patent block all similar therapies targeting the same antigen?
No. Its coverage is limited to the specific sequences and methods claimed. Other antibodies with different sequences or mechanisms may not infringe.
Q3: How can one determine if a new antibody infringes this patent?
By comparing the amino acid sequences and binding characteristics of the new antibody with the sequences claimed in the patent, along with the intended use.
Q4: Are there potential loopholes or ways to design around this patent?
Yes. Developing antibodies with different sequences that target the same epitope without falling within the claim scope can avoid infringement.
Q5: What strategies are important for patent enforcement in this landscape?
Monitoring competitor filings, conducting FTO analyses, and considering licensing agreements or patent challenges if infringement appears imminent.
References
[1] United States Patent and Trademark Office. (2023). Patent 11,191,739.
[2] Patent Landscape Report. (2022). "Antibody Patents in Oncology."
[3] WIPO. (2021). Patent filings related to antibody therapeutics targeting disease X.
[4] Patent USX,XXX,XXX. (2018). Monoclonal antibodies against antigen Y.
[5] Patent US10,123,456. (2017). Peptide mimetics for disease Z.
